1. Eur Respir J. 2021 Jan 21;57(1):2002161. doi: 10.1183/13993003.02161-2020.
Print  2021 Jan.

Ivacaftor modifies cystic fibrosis neutrophil phenotype in subjects with R117H 
residual function CFTR mutations.

Hardisty GR(1), Law SM(1), Carter S(2), Grogan B(2), Singh PK(3), McKone EF(2), 
Gray RD(4).

Author information:
(1)University of Edinburgh, Centre for Inflammation Research, Edinburgh, UK.
(2)St Vincent's Hospital, University College Dublin, Dublin, Ireland.
(3)Dept of Microbiology, University of Washington School of Medicine, Seattle, 
WA, USA.
(4)University of Edinburgh, Centre for Inflammation Research, Edinburgh, UK 
r.d.gray@ed.ac.uk.

CFTR modulation leads to changes in neutrophil phenotype even in patients with 
residual function CFTR mutations https://bit.ly/2EUk7xH

DOI: 10.1183/13993003.02161-2020
PMCID: PMC7817919
PMID: 32855222 [Indexed for MEDLINE]

Conflict of interest statement: Conflict of interest: G.R. Hardisty has nothing 
to disclose. Conflict of interest: S.M. Law has nothing to disclose. Conflict of 
interest: S. Carter has nothing to disclose. Conflict of interest: B. Grogan has 
nothing to disclose. Conflict of interest: P.K. Singh reports grants from 
Vertex, during the conduct of the study. Conflict of interest: E.F. McKone 
reports grants from Vertex, during the conduct of the study; personal fees for 
advisory board work from Vertex Pharmaceuticals, outside the submitted work. 
Conflict of interest: R.D. Gray reports personal fees from Vertex 
Pharmaceuticals, outside the submitted work.